Professor Sean Tu was interviewed for and cited in a Stat News article about a patent infringement lawsuit filed by Regeneron Pharmaceuticals against Amgen. Regeneron is arguing that Amgen is infringing on its patent for its drug, Eylea, an injectable used for treating eye diseases such as wet age-related macular degeneration, by creating a biosimilar competitor. According to the article, “the case is being closely watched by companies that sell biosimilar medicines amid concerns that the U.S. patent system is being gamed in ways that critics say can maintain high prices for medicines.”